Synergy Pharmac: (NASD: SGYP)

$5.30

0.21 (4.13%)

Volume 3,415,466

May 17 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		5.00 - 5.45
	
		52wk Low - High
		2.98 - 7.44
	
		Previous Close
		5.09
	
		Avg. Volume
		1,124,606
	
		Industry
		MED-DRUGS
	
		Market Cap
		388.96 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.39
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.88
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		88 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/13/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.88
                        
                            Current Quarter Estimate
                            -0.22
                        
                            Most Accurate Estimate
                            -0.22
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            09-15-2013
                        
                            EPS Last Year
                            NA
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.   
Full SGYP Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
SGYP Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.22	-0.23	-0.88	-0.98
Number of Estimates	2	2	3	2
Low Estimate	-0.24	-0.23	-1.00	-1.06
High Estimate	-0.21	-0.22	-0.71	NA
Year Ago EPS	NA	-0.15	-0.59	-0.88
EPS Growth	NA	-50.00%	-49.72%	-10.94%

More SGYP Estimates

Average Earnings Estimates for SGYP

EPS Growth for SGYP

Industry Analysis

Name	Symbol	Previous Close
SYNERGY PHARMAC	SGYP	5.30
JAZZ PHARMACEUT	JAZZ	58.36
SALIX PHARM-LTD	SLXP	59.28
SANTARUS INC	SNTS	21.91
USANA HLTH SCI	USNA	65.46
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.83
CELL THERAPEUT	CTIC	1.16
CUBIST PHARM	CBST	49.51
ELAN CP PLC ADR	ELN	11.67

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Synergy Pharma Posts Wider Loss

May 15, 2013

Bearish MACD for Synergy Pharmaceuticals Inc.

Apr 26, 2013

Synergy Pharma Prices Public Offering

Apr 12, 2013

Synergy Pharma to Raise Funds

Apr 10, 2013

Synergy Posts Wider Loss

Mar 20, 2013

Synergy Starts SP-333 Phase I Study

Jan 29, 2013

Synergy/Callisto Merger Approved

Jan 17, 2013

Positive Results on SGYP Candidate

Jan 03, 2013

More SGYP Zacks Commentary

Financials

EPS TTM	NA
Sales	NA
Net Income	-51
Price/Earnings	NA
Price/Book	14.11
Price/Cash Flow	NA
Price/Sales	NA

More SGYP Financials

News

Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index - Globenewswire

May 14, 2013

Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results - Globenewswire

May 9, 2013

Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on Plecanatide and SP-333 at the 15th Annual TIDES Summit - Globenewswire

May 9, 2013

Thursday 4/25 Insider Buying Report: SGYP, CFNL - Marketnewsvideo.Com

Apr 25, 2013

Synergy Pharmaceuticals Inc concludes USD84.5m public offering - M2

Apr 17, 2013

Synergy Pharmaceuticals raises $90.06 million in public offering of common stock - Datamonitor Financial Deals Tracker

Apr 17, 2013

Synergy Pharma Reports Completion of Public Offering of Shares, Received Net Proceeds $84.5M - Benzinga

Apr 16, 2013

Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock - Globenewswire

Apr 16, 2013

See All News Stories on SGYP

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	4
Average Target Price	12.13
Industry Rank by ABR	88 out of 265
Rank in Industry	83 out of 91

More SGYP Broker Recommendations

Day Low - High	5.00 - 5.45
52wk Low - High	2.98 - 7.44
Previous Close	5.09
Avg. Volume	1,124,606
Industry	MED-DRUGS
Market Cap	388.96 M
Div - Yield	0.00 - 0.00
Beta	0.39
PE (Forward)	0.00
Current Year Est.	-0.88
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.88
Current Quarter Estimate	-0.22
Most Accurate Estimate	-0.22
Earnings ESP	0.00%
Next Earnings Report Date	09-15-2013
EPS Last Year	NA
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Synergy Pharmac: (NASD: SGYP)

$5.30

0.21 (4.13%)

Volume 3,415,466

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description